← Back to Screener
Neuropace, Inc. Common Stock (NPCE)
Price$15.48
Favorite Metrics
Price vs S&P 500 (26W)36.27%
Price vs S&P 500 (4W)9.30%
Market Capitalization$525.54M
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)6.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)29.99%
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)-1.54%
Gross Margin (TTM)77.23%
Net Profit Margin (TTM)-21.47%
EPS (TTM)$-0.66
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-0.66
Revenue Growth (5Y)19.44%
EPS (Annual)$-0.66
ROI (Annual)-27.55%
Gross Margin (Annual)77.23%
Net Profit Margin (5Y Avg)-57.82%
Cash / Share (Quarterly)$1.82
Revenue Growth QoQ (YoY)23.86%
ROA (Last FY)-20.33%
Revenue Growth TTM (YoY)25.13%
EBITD / Share (TTM)$-0.51
ROE (5Y Avg)-159.09%
Operating Margin (TTM)-16.84%
Cash Flow / Share (Annual)$-0.34
P/B Ratio27.61x
P/B Ratio (Quarterly)27.02x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.63x
Net Interest Coverage (TTM)-3.83x
ROA (TTM)-20.01%
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)5.28x
Quick Ratio (Quarterly)4.25x
3-Month Avg Trading Volume0.21M
52-Week Price Return46.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.62
P/S Ratio (Annual)5.26x
Asset Turnover (Annual)0.95x
52-Week High$18.98
Operating Margin (5Y Avg)-45.53%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)40.80%
26-Week Price Return40.25%
Quick Ratio (Annual)4.25x
13-Week Price Return-7.69%
Total Debt / Equity (Annual)3.09x
Current Ratio (Quarterly)5.28x
Enterprise Value$562.733
Revenue / Share Growth (5Y)11.44%
Asset Turnover (TTM)0.93x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.50x
Pretax Margin (Annual)-21.47%
Cash / Share (Annual)$1.82
3-Month Return Std Dev43.19%
Gross Margin (5Y Avg)74.03%
Net Income / Employee (TTM)$-0
ROE (Last FY)-112.79%
Net Interest Coverage (Annual)-3.73x
EPS Basic Excl Extra (Annual)$-0.66
Receivables Turnover (TTM)7.26x
Total Debt / Equity (Quarterly)3.09x
EPS Incl Extra (TTM)$-0.66
Receivables Turnover (Annual)7.26x
ROI (TTM)-27.06%
P/S Ratio (TTM)5.26x
Pretax Margin (5Y Avg)-57.82%
Revenue / Share (Annual)$3.06
Tangible BV / Share (Annual)$1.39
Price vs S&P 500 (52W)16.47%
Year-to-Date Return1.10%
5-Day Price Return6.55%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-29.58%
Net Profit Margin (Annual)-21.47%
Month-to-Date Return18.71%
Cash Flow / Share (TTM)$-1.49
EBITD / Share (Annual)$-0.51
Operating Margin (Annual)-16.84%
LT Debt / Equity (Annual)3.09x
ROI (5Y Avg)-38.63%
LT Debt / Equity (Quarterly)3.09x
EPS Basic Excl Extra (TTM)$-0.66
P/TBV (Quarterly)14.44x
P/B Ratio (Annual)27.02x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)-21.47%
Book Value / Share (Annual)$0.57
Price vs S&P 500 (13W)-8.38%
Beta1.92x
Revenue / Share (TTM)$2.99
ROE (TTM)-105.67%
52-Week Low$7.56
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
NPCENeuropace, Inc. Common Stock | 5.26x | 19.44% | 77.23% | -16.84% | $15.48 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
NeuroPace develops implantable neuromodulation systems to treat epilepsy through its RNS System, which continuously monitors brain electrical activity and delivers personalized seizure prevention therapy. The company's comprehensive platform integrates implantable devices, clinical monitoring software, and patient management tools that support ongoing treatment outcomes. NeuroPace generates revenue from device sales, implantation procedures, and subscription-based patient management services.